EMADOC-1700519818-2039288

European Medicines Agency decision

EMA/PE/0000231022

of 15 April 2025

on the acceptance of a modification of an agreed paediatric investigation plan for meropenem trihydrate, vaborbactam (Vaborem) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

EMA/PE/0000231022

of 15 April 2025

on the acceptance of a modification of an agreed paediatric investigation plan for meropenem trihydrate, vaborbactam (Vaborem)in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0229/2015 issued on 22 October 2015, the decision P/0267/2020 issued on 15 July 2020, the decision P/0260/2021 issued on 9 July 2021 and the decision P/0530/2023 issued on 29 December 2023,

Having regard to the application submitted by Menarini International Operations Luxembourg S.A. on 19 November 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 February 2025, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for meropenem trihydrate, vaborbactam (Vaborem), including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Menarini International Operations Luxembourg S.A., 1 Avenue De La Gare, 1611 – Luxemburg, Luxembourg.

EMADOC-1700519818-1811975 Corr[1]
Amsterdam, 28 February 2025

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA/PE/0000231022

Scope of the application

Active substance(s):

Meropenem (trihydrate), Vaborbactam

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of Gram-negative bacterial infections

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Menarini International Operations Luxembourg S.A.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Menarini International Operations Luxembourg S.A. submitted to the European Medicines Agency on 19 November 2024 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0229/2015 issued on 22 October 2015, the decision P/0267/2020 issued on 15 July 2020, the decision P/0260/2021 issued on 9 July 2021 and the decision P/0530/2023 issued on 29 December 2023.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

[1] 24 March 2025

The procedure started on 2 January 2025.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of Gram-negative bacterial infections

2.1.1. Indication(s) targeted by the PIP

Treatment of complicated urinary tract infection (cUTI) including pyelonephritis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of an age-appropriate formulation for intravenous use
Non-clinical studies	**Study 2** Dose-range finding study to support dose-selection for the main juvenile toxicity study and to determine maximum tolerated dose of combination **Study 3** Definitive juvenile toxicity study to assess toxicity of vaborbactam in combination with meropenem in juvenile animals and to evaluate delayed onset of toxicity and recovery from possible toxic effects during the recovery period
Clinical studies	**Study 4** Open-label, single dose trial to evaluate pharmacokinetics, safety and tolerability study of meropenem in combination with vaborbactam in children from 3 months to less than 18 years of age with confirmed or suspected bacterial infections requiring intravenous antibiotics **Study 5** Study deleted in EMEA-001731-PIP01-14-M03

	Study 6 Study deleted in EMA/PE/0000231022 of February 2025. **Study 8** Study added in EMEA-001731-PIP01-14-M03 Open label trial to evaluate pharmacokinetics, safety and efficacy of meropenem in combination with vaborbactam in paediatric patients from birth to less than 18 years of age with suspected or confirmed Gram negative infections, including but not restricted to complicated urinary infection (cUTI) / acute pyelonephritis (AP).
Extrapolation, modelling and simulation studies	**Study 7** Population PK/PD modelling and simulation study for dose selection across paediatric age groups for patients with infections caused by Gram-negative bacteria.
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of Treatment of Gram-negative bacterial infections

Authorised indication(s):

- Complicated urinary tract infection (cUTI), including pyelonephritis
- Complicated intra-abdominal infection (cIAI)
- Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).
- Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
- Vaborem is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment option Invented name(s): Vaborem
  - Invented name(s): Vaborem
  - Authorised pharmaceutical form(s): powder for concentrate for solution for infusion (powder for concentrate)
  - Authorised route(s) of administration: intravenous use
  - Authorised via centralised procedure